Skip to main content

Advertisement

Table 3 Overall survival and progression-free survival from the start of second-line therapy for individual drugs and from the start of first-line therapy for the most common treatment sequences

From: Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry

Second-line targeted drug n Median OS (95% CI) Median PFS (95% CI) Overall response rate, n (%) a Disease control rate n (%)a
Everolimus 520 17.0 months (14.5–19.5) 6.3 months (5.6–6.9) 30 (6.7) 201 (45.1)
Sorafenib 240 17.1 months (14.5–19.8) 5.8 months (4.7–6.8) 23 (9.9) 113 (48.7)
Sunitinib 228 15.4 months (11.0–19.7) 5.7 months (4.4–7.0) 25 (12.1) 73 (35.3)
Sunitinib → everolimus 390 37.2 months (31.5–42.9) 22.7 months (19.5–26.0)b 32 (8.2) 176 (45.1)
Sunitinib → sorafenib 232 32.7 months (27.1–38.2) 19.0 months (15.8–22.3 b 24 (10.3) 119 (51.3)
Sorafenib → sunitinib 139 31.8 months (25.8–37.7) 18.5 months (16.2–20.7)b 19 (13.7) 54 (38.8)
Sorafenib → everolimus 93 32.2 months (26.0–38.3) 21.4 months (18.0–24.9)b 3 (3.2) 52 (55.9)
  1. 95%CI 95% confidence intervals, OS overall survival, PFS progression-free survival
  2. aData for best response assessment were available for 446, 232, and 207 patients treated with everolimus, sorafenib, and sunitinib, respectively
  3. bPFS for sequences was the time from first-line treatment initiation to the date of documented progression on the second-line therapy